Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017. (CROSBI ID 252593)

Prilog u časopisu | stručni rad | međunarodna recenzija

Jakšić, Branimir ; Pejša, Vlatko ; Ostojić- Kolonić, Slobodanka ; Kardum-Skelin, Ika ; Bašić- Kinda, Sandra ; Coha, Božena ; Gverić- Krečak, Velka ; Vrhovac, Radovan ; Jakšić, Ozren ; Aurer, Igor et al. Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017. // Acta clinica Croatica, 57 (2018), 1; 190-215. doi: 10.20471/acc.2018.57.01.27

Podaci o odgovornosti

Jakšić, Branimir ; Pejša, Vlatko ; Ostojić- Kolonić, Slobodanka ; Kardum-Skelin, Ika ; Bašić- Kinda, Sandra ; Coha, Božena ; Gverić- Krečak, Velka ; Vrhovac, Radovan ; Jakšić, Ozren ; Aurer, Igor ; Sinčić-Petričevi, Jasminka ; Načinović- Duletić, Antica ; Nemet, Damir

engleski

Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017.

Recent developments in the diagnosis and treatment of chronic lymphocytic leukemia (B- CLL) have led to change of approach in clinical practice. New treatments have been approved based on the results of randomized multicenter trials for first line and for salvage therapy, and the results of numerous ongoing clinical trials are permanently providing new answers and further refining of therapeutic strategies. This is paralleled by substantial increase in understanding the disease genetics due to major advances in the next generation sequencing (NGS) technology. We define current position of the Croatian Cooperative Group for Hematologic Disease on diagnosis and treatment of CLL in the transition from chemo-immunotherapy paradigm into a new one that is based on new diagnostic stratification and unprecedented therapeutic results of B-cell receptor inhibitors (BRI) and Bcl-2 antagonists. This is a rapidly evolving field as a great number of ongoing clinical trials constantly accumulate and provide new knowledge. We believe that novel therapy research including genomic diagnosis is likely to offer new options that will eventually lead to time limited therapies without chemotherapy and more effective clinical care for B-CLL based on individualized precision medicine.

chronic lymphocytic leukemia ; practice guidelines as topic ; precision medicine ; Croatia ; KROHEM

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

57 (1)

2018.

190-215

objavljeno

0353-9466

1333-9451

10.20471/acc.2018.57.01.27

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost